# Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases

> **NCT03388255** · PHASE4 · TERMINATED · sponsor: **Mastelli S.r.l** · enrollment: 25 (actual)

## Conditions studied

- Scleroderma Disease

## Interventions

- **DRUG:** Polydeoxyribonucleotides

## Key facts

- **NCT ID:** NCT03388255
- **Lead sponsor:** Mastelli S.r.l
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-08
- **Primary completion:** 2019-10-30
- **Final completion:** 2019-10-31
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** the clinical center has too much difficulty recruiting as a rare condition
- **Last updated:** 2021-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03388255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03388255, "Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03388255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*